|
|
Substance Name: Gemcitabine hydrochloride [USAN:USP]
RN: 122111-03-9
UNII: U347PV74IL
InChIKey: OKKDEIYWILRZIA-OSZBKLCCSA-N
Note
- NCI: Gemcitabine hydrochloride is approved by the Food and Drug Administration (FDA) to be used by itself to treat pancreatic cancer that is advanced or has metastasized (spread to other parts of the body). It is used in patients who cannot be treated with surgery and have already been treated with other chemotherapy.[National Cancer Institute]
Molecular Formula
- C9-H11-F2-N3-O4.Cl-H
Molecular Weight
- 299.6598
- All
- Classifications
- Links to Resources
- Names & Synonyms
- Registry Numbers
- Formulas
- Structure Descriptors
- Toxicity
Classification Codes
- Anti-Infective Agents
- Antimetabolites
- Antimetabolites, Antineoplastic
- Antineoplastic
- Antineoplastic Agents
- Antiviral Agents
- Enzyme Inhibitors
- Immunologic Factors
- Immunosuppressive Agents
- Noxae
- Radiation-Sensitizing Agents
- Reproductive Effect
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Gemcitabine hydrochloride [USAN:USP]
Synonyms
- 2',2'-Difluorodeoxycytidine monohydrochloride
- 2'-Deoxy-2',2'-difluorocytidine monohydrochloride
- 2'-Deoxy-2',2'-difluorocytidine monohydrochloride (beta-isomer)
- Gemcitabine HCl
- Gemcitabine hydrochloride
- Gemzar
- LY188011 hydrochloride
- UNII-U347PV74IL
Systematic Name
- Cytidine, 2'-deoxy-2',2'-difluoro-, monohydrochloride
Registry Numbers
CAS Registry Number
- 122111-03-9
FDA UNII
- U347PV74IL
Related Registry Numbers
- 103882-84-4
- 95058-81-4
System Generated Number
- 0122111039
Molecular Formulas
Molecular Formula
- C9-H11-F2-N3-O4.Cl-H
Molecular Formula Fragments
- C9-H11-F2-N3-O4
- Cl-H
- COMPONENT
Structure Descriptors
InChI
InChI=1S/C9H11F2N3O4.ClH/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17;/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17);1H/t4-,6-,7-;/m1./s1InChIKey
OKKDEIYWILRZIA-OSZBKLCCSA-NSmiles
Cl.NC1=NC(=O)Toxicity
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
mouse | LD50 | intravenous | 500mg/kg (500mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 42, Pg. 391, 2000. | |
rat | LD50 | intravenous | 236mg/kg (236mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 42, Pg. 391, 2000. | |
women | TDLo | parenteral | 300mg/kg/12W- (300mg/kg) | LUNGS, THORAX, OR RESPIRATION: "FIBROSIS, FOCAL (PNEUMOCONIOSIS)" LUNGS, THORAX, OR RESPIRATION: CONSOLIDATION LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Cancer Vol. 80, Pg. 286, 1997. |